Two physiologically based pharmacokinetic models for trichloroethylene (TCE) in mice and humans were calibrated with new toxicokinetic data sets. Calibration is an important step in model development, essential to a legitimate use of models for research or regulatory purposes. A Bayesian statistical framework was used to combine prior information about the model parameters with the data likelihood to yield posterior parameter distributions. For mice, these distributions represent uncertainty. For humans, the use of a population statistical model yielded estimates of both variability and uncertainty in human toxicokinetics of TCE. After adjustment of the models by Markov chain Monte Carlo sampling, the mouse model agreed with a large part of the data. Yet, some data on secondary metabolites were not fit well. The posterior parameter distributions obtained for mice were quite narrow (coefficient of variation [CV] of about 10 or 20%), but these CVs might be underestimated because of the incomplete fit of the model. The data fit, for humans, was better than for mice. Yet, some improvement of the model is needed to correctly describe trichloroethanol concentrations over long time periods. Posterior uncertainties about the population means corresponded to 10-20% CV. In terms of human population variability, volumes and flows varied across subject by approximately 20% CV. The variability was somewhat higher for partition coefficients (between 30 and 40%) and much higher for the metabolic parameters (standard deviations representing about a factor of 2). Finally, the analysis points to differences between human males and females in the toxicokinetics of TCE. The significance of these differences in terms of risk remains to be investigated. 
New physiologically based pharmacokinetic (PBPK) models of trichloroethylene (TCE) (3, 4) . This statistical methodology is gaining interest and is establishing itself for the calibration and validation of PBPK models (3, (5) (6) (7) (8) . Beyond improving the fit, this method also provides distributions of prediction estimates directly usable as inputs for uncertainty analysis of cancer dose-response relationships.
An interesting aspect of the human data analyzed here is that they have been collected individually on a number of male and female volunteers. A hierarchical population model (4, 5) deconvolves the various levels of variability present in the data. Such a model, of which the PBPK model is just a component, is easily calibrated with Bayesian numerical methods. This offers a unique opportunity to examine separately the important issues of variability and uncertainty in human toxicokinetics of trichloroethylene.
Methods Data
Mice. Groups of male B6C3F, mice (body weight [bw] 25-30 g) were exposed to TCE or its metabolites by intravenous (i.v.) injection (9) or by oral gavage (1) .
All i.v. doses were equal to 100 mg of the compound administered per kilogram of body weight. After (15) for the population variances 12.
Values for the hyperparameters M were set on the basis of the parameter values used by Fisher (2) , or when applicable, on the basis of the posterior parameter distributions obtained from the analysis of the Clewell et al. model (12, 13) . To set S, a distinction was made between the physiological parameters or partition coefficients (which are quite well known) and the other metabolic or pharmacokinetic parameters (which are model specific and little known a priori). For first group of parameters uncertainties of the order of 20-50% were assigned (3, 5, 6) . For the second group of parameters, a vague distribution was assumed and S was set to correspond to a factor of 5. All priors on p were truncated to ±2 x S.
The coefficient of the inverse-gamma prior on 12 was set to the posterior values found in the previous analysis (13) 
Statistical Computation ofPosterior Parameter Distributions
From Bayes' theorem, the joint posterior distribution of the parameters to estimate, P(O, a2, p, 12ly, 9, E, t, M, S, La), in the case ofhumans, is proportional to the likelihood of the data multiplied by the parameters' priors: P(O, a2, l, 121y, 9, E, t, M) S,sy ) P(y10,a2,9,E,t) * AOIp,12) . p(a2).
P(pIM,S) * p(1212) [1] A similar, but simpler, expression can be obtained in the case of the mouse model. For mice and humans, the likelihood term is given by the normal measurement model: log(y) -N(log f(O,p,E,t,)02) [2] As mentioned above, the The graph is presented on log-log scale, since the errors are assumed to be lognormally distributed and the data span a wide range. Most of the residuals are contained within a factor of 3 along the diagonal, but quite a few reach a factor of 10 or even a factor of 100. Figures 2-7 show all the gavage data and corresponding predictions in the liver as a function of time. Basically the model reproduces correctly the profiles for TCE and TCA. TCOH and TCOG concentrations are less well predicted. CH and DCA concentrations and TCOG excreted are rather poorly fitted. The fact that each data point represents a different group of animals may explain the noise present in the data. However, some differences between model and data appear to be systematic ( Figure 3, for example) .
Posterorparameter distbutions. The joint distribution of all parameters is obtained in output of the MCMC simulations. This allows consideration of marginal distributions (distributions of the parameters considered individually) and also ofcorrelations ofany order. the inferences and predictions presented in the following were made.
Quality ofdata adjustment. Figure 8 TCOH can be obtained for the volunteers observed up to 22 hr ( Figure 10) . Most (Figure 12 ). Posterior parameter distributions. The population SDs measure between-subject variability. They are also affected by uncertainty (i.e., the population SD cannot be exactly computed from a finite sample).
The posterior means for several parameters are quite far from their prior estimates. The location of the blood over air partition coefficient, PB, is shifted from 13.7 (±20%) to 18 (± 10%). The location of other partition coefficients (slowly perfused muscle over blood and richly perfused liver over blood) is also changed. The largest shifts are observed for metabolic parameters. The estimate of the scaling coefficient of TCE Vmax in liver (VMAXC) is 4.22 (±20%) instead of 43.8. A large uncertainty existed on that prior estimate, but 4.22 is still outside its prior 95% confidence interval (lower bound at 12.6). Therefore, there appears to be a conflict between the data studied here and the data studied previously. Note also that the posterior mean of the fraction TCE converted to TCOH (POH) is quite lower than a priori estimated. The posterior means of the scaling coefficient of Vmax for TCOH metabolism (VMTCOC) and of the scaling coefficient of the rate constant from TCOH to TCA (KOCHC) are much increased but not Estimates of population variability are given by the posteriors of the population SDs, E. Volumes and flows appear to vary across subject by approximately 20% (CV). The variability is somewhat higher for partition coefficients (between 30 and 40% CVs). It is much higher for the metabolic parameters (SDs representing approximately a factor of 2 difference). For example, the lowest rate constant scaling coefficient for TCA metabolism (KITMETC) is 0.12 x 1.6 hrl (subject 1 1OF) and the highest is 1.1 x 1.25 hr'1 (subject 10IF, the subject with lowest TCA levels on Figure 11 ). For the scaling coefficient of the rate constant ofTCA loss to urine (KRTCC), the values range from 0.13 x 1.2 hr'1 (subject 106M) to 3.4 x 1.2 hr-1 (subject 1 Time (hr) Figure 10 . Predicted (solid lines) and observed (points) time course of TCOH concentration in venous blood of human volunteers exposed by inhalation to various concentrations of TCE. These volunteers were followed for up to 22 hr. The error bars presented on a data point correspond to ±2 estimated measurement SD (the size of the error is the same for all points). '20' 250 Time (hr) Figure 11 . Predicted (solid lines) and observed (points) time course of TCA concentration in venous blood of human volunteers exposed by inhalation to various concentrations of TCE. The error bars presented on a data point correspond to ±2 estimated measurement SD (the size of the error is the same for all points). (12, 23) ] with this data set, which would allow a formal comparison of the competing models on the basis of a common measure of goodness of fit, such as likelihood ratios.
The posterior parameter distributions obtained for mice are quite narrow (with CVs of about 10 or 20%), indicating that the data are strongly informative for most parts of the model. Indeed, as indicated above, some parameters or processes might need to be added for a better fit and the model is somewhat minimal with respect to the data. However, it should be kept in mind that the fit is not excellent, and that may overconstrain the posterior distributions. Part of the high covariance between parameters may also be due to overconstraining. It is possible to model statistically the lack of fit by including an autocorrelation between data points (24). This has not been attempted here and could be a useful improvement. Note that the posterior uncertainty for the metabolic parameters would have been further underestimated if all physiological parameters had been set to predefined values.
The human model, even though complex, also has difficulties in fitting all the data. This is true in particular for TCOH concentrations over a long period of time, and some improvement of the model in that respect may be needed. Similarly, the adiposity of the subjects (a measured covariate) does not fit well with the estimated fraction of body weight as fat. It is possible that the pharmacokinetic compartment "fat" is not well estimated by external adiposity measurements, in particular for extreme values. It also appears that the model may not be able to describe correctly outlying subjects like subject 106M. This could be due to the PBPK model, which lacks some component important for such a subject. The misfit for that subject could also be due to a lack of flexibility of the statistical model adopted here (log-normal distributions of the parameters in the population). A possibility for checking would be to fit the data of only that subject to determine if a good fit could be obtained.
The human posterior parameter distributions agree in general quite well with the corresponding priors, with reduced uncertainty (since information from the data has been gained). SDs about the posterior means are quite low and correspond to a 10-20% CV: The parameter values are overall quite well identified by the data. There is, however, a conflict for the values of VMAXC between the values previously found (3) and the ones obtained here. This is an important parameter and a good characterization is important. The difference could be due to conflicts between the data analyzed here and the previous data. For example, extensive TCOH data are available here. It is also possible that the conflict is due to differences in human model structures. A solution to this dilemma would be to take the model of Clewell et al. (12) and fit it to the data of Fisher (2) to obtain an estimate of VMAXC with the same data set. In any case, it is not obvious that the differences in parameter values would result in notable differences when predicting toxicologically relevant end points, such as internal TCA concentrations. This remains to be checked.
Volumes and flows appear to vary across subject by 20% (CV), approximately. The variability is somewhat higher for partition coefficients (between 30 and 40% CVs) and much higher for the metabolic parameters (SDs representing about a factor of 2 difference). This is similar to what was found for a small group of human volunteers exposed to tetrachloroethylene (5) . Differences appear to exist between sexes in the toxicokinetics of TCE. There are differences between males and females in alveolar ventilation and adiposity for the population sample studied. This should be true for compounds other than TCE and shows that the model scaling could be improved. More important for TCE kinetics are the findings that females have higher TCOH body over blood partition coefficients, lower TCA body over blood partition coefficients, higher Vm,, over Km ratios for TCOH glucuronidation, higher rate constant scaling coefficients for TCOH to TCA, and higher rate constant scaling coefficients for TCA urinary excretion. Note that the statistically highly significant differences found for these parameters should be interpreted with some caution. They are conditional on the model structure being correct. At least, at this point, it can be said that there are most certainly differences in the kinetic behavior of TCE between the males and females of the sample studied. It would have been hard to reach that conclusion without the statistical adjustment of a model, given the multiple exposure levels, differences in body weight, nonlinear kinetics, etc. Still, these differences may not be significant in terms of TCE toxicity (i.e., biologically significant). It 
